Pharmaceutical company Takeda continues to work with the U.S. Food and Drug Administration (FDA) to bring NATPARA® back on the market.  Unfortunately, there is more work to do. 

 Click on the link below to read Takeda’s recent regulatory update.  According to the update, Takeda plans to continue providing NATPARA® to those enrolled in its Special Use Program. 

Leave a Reply

Your email address will not be published. Required fields are marked *